Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1243561

NCc1cccc(C(=O)Nc2ccc(Nc3cc(-c4cccc5c4oc4ccccc45)ncn3)cc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 6/20 0.41
PIP4K2C Q8TBX8 2/20 0.40
ABL1 P00519 5/20 0.39
BCR P11274 4/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
AURKA O14965 2/20 0.38
RPS6KB1 P23443 2/20 0.38
PIP4K2A P48426 1/20 0.37
PIP4K2B P78356 1/20 0.37
PIKFYVE Q9Y2I7 1/20 0.37
LOX P28300 4/20 0.37
EGFR P00533 2/20 0.37
ERBB3 P21860 2/20 0.37
KLKB1 P03952 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1242277 0.95 PIP4K2C (0.43) LOXL2PIP4K2CKDM4EMAPTAURKA
SCHEMBL1241068 0.94 PIP4K2C (0.44) LOXL2PIP4K2CKDM4EMAPTAURKA
Trifluoroacetic Acid SCHEMBL4384220 0.94 PIP4K2C (0.39) LOXL2PIP4K2CABL1BCRKDM4E
Trifluoroacetic Acid SCHEMBL1244312 0.94 PIP4K2C (0.45) LOXL2PIP4K2CABL1BCRKDM4E
Trifluoroacetic Acid SCHEMBL1244552 0.90 PTGS1 (0.43) PIP4K2CABL1BCRKDM4EMAPT
Trifluoroacetic Acid SCHEMBL1244801 0.90 PIP4K2C (0.39) LOXL2PIP4K2CABL1BCRKDM4E
Trifluoroacetic Acid SCHEMBL1244929 0.90 LOXL2 (0.37) LOXL2PIP4K2CABL1BCRKDM4E
SCHEMBL1244601 0.89 PIP4K2C (0.47) LOXL2PIP4K2CMAPTAURKARPS6KB1
Trifluoroacetic Acid SCHEMBL1244400 0.89 PIP4K2C (0.37) PIP4K2CABL1BCRKDM4EMAPT
Trifluoroacetic Acid SCHEMBL1242002 0.89 PIP4K2C (0.43) PIP4K2CABL1BCRKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879853-B2 tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer BAYER SCHERING PHARMA AG (DE) 2011-02-01 US disclosed
EP-1763526-B1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2009-06-24 EP disclosed
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors ATLANTA PHARMA AG (DE) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors CDK2, DCK, DTYMK LOXL2 3815/4885PIP4K2C 52/4885ABL1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.